A-M Grumpelt1, A Ignatov1, S N Tchaikovski2, E Burger3, S-D Costa1, H Eggemann4. 1. University Womens Hospital, Otto-von-Guericke University, Gerhard-Hauptmann-Str. 35, 39108, Magdeburg, Germany. 2. University Womens Hospital, RWTH Aachen University, Aachen, Germany. 3. Cancer Registry Magdeburg, Magdeburg, Germany. 4. University Womens Hospital, Otto-von-Guericke University, Gerhard-Hauptmann-Str. 35, 39108, Magdeburg, Germany. holm.eggemann@med.ovgu.de.
Abstract
INTRODUCTION: Elderly breast cancer patients aged ≥75 years are underrepresented in most studies. Therefore, data on cancer characteristics, adjuvant treatment and survival in elderly patients are missing. PATIENTS AND METHODS: In this retrospective study, we compared tumor characteristics and adjuvant therapy in 973 women with invasive, non-metastasized breast cancer aged ≥75 years with 3377 younger postmenopausal patients (50-74 years old). Time dynamics of tumor characteristics were investigated, comparing two observation periods between the years 2000-2004 versus 2005-2008. RESULTS: Compared to younger women, older patients were more often treated with mastectomy and less likely to receive adjuvant treatment. Although the overall survival rate increased over the observation period in both age groups, the older study group was characterized by shorter disease-free survival. Additionally, we observed an increase in about 1.65 years in the age at diagnosis as well as an increasing rate of breast-conserving surgery and sentinel lymph node biopsy for the whole study population between 2000 and 2008. Furthermore, we found a reduction in the proportion of estrogen receptor-positive tumors in the younger women and a decrease in G3-tumors in both age groups over the study time. CONCLUSION: The older group's reduced disease-free survival could be explained by the tumor characteristics and differences in the adjuvant treatment. Remarkably, elderly women are more likely to be overtreated surgically while being undertreated in terms of adjuvant therapy.
INTRODUCTION: Elderly breast cancerpatients aged ≥75 years are underrepresented in most studies. Therefore, data on cancer characteristics, adjuvant treatment and survival in elderly patients are missing. PATIENTS AND METHODS: In this retrospective study, we compared tumor characteristics and adjuvant therapy in 973 women with invasive, non-metastasized breast cancer aged ≥75 years with 3377 younger postmenopausal patients (50-74 years old). Time dynamics of tumor characteristics were investigated, comparing two observation periods between the years 2000-2004 versus 2005-2008. RESULTS: Compared to younger women, older patients were more often treated with mastectomy and less likely to receive adjuvant treatment. Although the overall survival rate increased over the observation period in both age groups, the older study group was characterized by shorter disease-free survival. Additionally, we observed an increase in about 1.65 years in the age at diagnosis as well as an increasing rate of breast-conserving surgery and sentinel lymph node biopsy for the whole study population between 2000 and 2008. Furthermore, we found a reduction in the proportion of estrogen receptor-positive tumors in the younger women and a decrease in G3-tumors in both age groups over the study time. CONCLUSION: The older group's reduced disease-free survival could be explained by the tumor characteristics and differences in the adjuvant treatment. Remarkably, elderly women are more likely to be overtreated surgically while being undertreated in terms of adjuvant therapy.
Entities:
Keywords:
Adjuvant treatment; Breast cancer; Elderly patients
Authors: Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Esther Bastiaannet; Johanneke E A Portielje; Cornelis J H van de Velde; Anton J M de Craen; Susanne van der Velde; Peter J K Kuppen; Lydia G M van der Geest; Maryska L G Janssen-Heijnen; Olaf M Dekkers; Rudi G J Westendorp; Gerrit-Jan Liefers Journal: Oncologist Date: 2011-03-15
Authors: Mara A Schonberg; Edward R Marcantonio; Donglin Li; Rebecca A Silliman; Long Ngo; Ellen P McCarthy Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Roberto Gennari; Giuseppe Curigliano; Nicole Rotmensz; Chris Robertson; Marco Colleoni; Stefano Zurrida; Franco Nolè; Filippo de Braud; Laura Orlando; Maria Cristina Leonardi; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Giuseppe Renne; Saverio Cinieri; Riccardo A Audisio; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhirsch Journal: Cancer Date: 2004-09-15 Impact factor: 6.860
Authors: N Honma; G Sakamoto; F Akiyama; Y Esaki; M Sawabe; T Arai; T Hosoi; N Harada; M Younes; K Takubo Journal: Histopathology Date: 2003-02 Impact factor: 5.087
Authors: Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes Journal: Lancet Oncol Date: 2010-11-17 Impact factor: 41.316
Authors: Julia Frebault; Carmen Bergom; Chandler S Cortina; Monica E Shukla; Yiwen Zhang; Chiang-Ching Huang; Amanda L Kong Journal: Clin Breast Cancer Date: 2021-07-16 Impact factor: 3.225
Authors: Jonathan Pruessmann; Telja Pursche; Friederike Hammersen; Alexander Katalinic; Dorothea Fischer; Annika Waldmann Journal: Breast Care (Basel) Date: 2020-05-13 Impact factor: 2.860
Authors: Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 50.717
Authors: E C Inwald; O Ortmann; M Koller; F Zeman; F Hofstädter; M Evert; G Brockhoff; M Klinkhammer-Schalke Journal: Breast Cancer Res Treat Date: 2017-02-15 Impact factor: 4.872